Mead Johnson and Company

Even though this vitamin was one of the earliest recognized and the chemical interrelations between the various available forms are relatively well known, the human needs are still uncertain from the quantitative standpoint. In 1932 Mead Johnson and Company offered a 15,000 award for which the following terms were set ... 

Kreighbaum W.E., Comer W.T. US Patent No. 4,234,595 November 18, 1980 Assigned Mead Johnson and Company, Evansville... 

Mead Johnson and Company British Patent 940, 540 October 30, 1963... 

The nicotinic acid assay on Dextrimaltose no. 2 was obtained throiigli the courtesy of Dr. Warren M. Cox, Jr., Mead Johnson and Company. Kach gram of Dextrimaltose contained 8.6 microgram. 

The Glebs (Richard became Bristol-Myers s CEO in 1972) continued to grow the company through acquisitions in advertising-intensive consumer products. In 1965 came the purchases of Brackett, producers of Windex, Draino, and O Cedar mops in 1967, of Mead Johnson, makers of infant formulas and children s vitamins, followed by Abbott Tresses and in 1971, of Ellen Kaye Cosmetics. Nearly all these acquisitions and smaller ones made during the 1960s were paid for by blocks of common stock. 

Ortho Pharmaceuticals, a subsidiary of Johnson Johnson, has had an ongoing contraceptive R D program. Eight companies that have discontinued Such R D are Syntex, Searle, Parke-Davis, Merck, Upjohn, Mead Johnson, Wyeth-Ayerst, and Eli Lilly (207). Wyeth-Ayerst, a subsidiary of American Home products, has renewed its contraceptive R D program in recent years, focusing on new forms of oral contraceptives (8,25 1). In addition, a relatively new, small firm, Gynco-Pharma, currently markets a copper IUD. Non-U.S. firms as well as universities and nonprofit foundations also carry on R D on new forms of birth control (207). 

Two case studies — one from AT T Wireless Services and one from Meade Johnson Nutritionals (MJN), a division of Bristol-Myers Squibb, illustrate early applications of the SCOR model.i The descriptions are summaries from presentations made by company managers at an SCC conference. Each... 

This term is the registered trademark of the commercially prepared protein formula sold by Mead Johnson Company of Evansville, Indiana. Ninety-five percent of the amino acid phenylalanine is removed from Lofenalac. It provides the basis for dietary management of phenylketonuria (PKU), an inborn error of metabolism. Most proteins contain 4 to 6% phenylalanine and would be detrimental to an infant with PKU. Lofenalac is used to meet the infant s protein and energy needs while the requirement for phenylalanine, an essential amino acid, is just satisfied—no excess—with foods whose phenylalanine content is known. 

---